SwitzerlandSwitzerland

Clariant to take over German Süd-Chemie AG for EUR2bn

18.02.2011

Muttenz/Munich – Swiss chemistry specialist Clariant AG had made a 2bn bid for Munich-based catalysis and adsorbents specialist Süd-Chemie aimed at taking over the controlling majority from two groups of stockholders. The transaction, which is based on definite agreements with One Equity Partners who hold 50.4% of Süd-Chemie’s shares and the family shareholders (46%), is still subject to clearance by competent merger control authorities. When the deal goes through, Clariant will bag more than 95% of the outstanding shares. Süd-Chemie has a strong R&D pipeline that addresses future needs of the chemistry industry. The company has developed a economically promising approach in advanced development stage to generate cellulosic ethanol from the world’s most common straw feeds – rice straw, corn stover and bagasse. The Sun Liquid process, which has been proven economically feasible at pilot scale, is ready to be tested in a demonstration plant later this year. The company aimed at licensing out the technology world-wide as entry point to plant-based C-2 chemistry building blocks for manufacture of bulk bioplastics such as polyethylene, polypropylene or polyvinyl chloride. As a global leader in process catalysis and adsorbents Süd-Chemie provides the missing link between chemical process engineering and biocatalysis. In 2010, the Munich-based company had a turnover of EUR1.225 billion and EBITDA of EUR 191 million. After the acquisition of Danish Danico by US chemistry giant DuPont, Süd-Chemie has become is the second strategic target involving a world-leading biotechnology product pipeline. The issue of new shares is subject to approval at the Clariant general meeting on March 31, 2011.

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/clariant-to-take-over-german-sued-chemie-ag-for-eur2bn.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.20 EUR418.5%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 24.05.2015

Current issue

All issues